EUVIMEDEUVIMED entdecken
Kohortenstudie

Biologic Efficacy by BMI in Moderate‐To‐Severe Psoriasis: A Real‐World Cohort Study

Xin Shen, Fan Wang, Rui Wang, Huan Liu, Erle Dang iD, Chen Yu iD, Gang Wang iD

Experimental Dermatology · 2026-04 · 35 (4)

DOI: 10.1111/exd.70252 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Experimental Dermatology, online erschienen am 13.04.2026. Verfasst von Xin Shen und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China. Hauptthemen laut MEDLINE: Psoriasis, Body Mass Index, Biological Products. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 33 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Obesity reduces response to biologic therapy in psoriasis, but comparative evidence across drug classes in Chinese patients is limited. A real‐world cohort of 891 adults with moderate‐to‐severe psoriasis initiating biologics between 2020 and 2025 was divided by baseline BMI (< 24 vs. ≥ 24 kg/m 2 ). PASI90 achievement at 2, 4, 6 and 12 months and drug survival were compared amongst IL‐17, IL‐23 and TNF‐α inhibitors. Amongst IL‐17 users, PASI90 rates in the non‐overweight group were consistently higher at 4, 6 and 12 months (all p < 0.05), whereas no BMI‐related differences were seen with TNF‐α or IL‐23 blockade. Within the non‐overweight stratum, IL‐17 and IL‐23 agents outperformed TNF‐α inhibitors at month 6 and yielded fewer switches ( p < 0.05). In the overweight/obese stratum, IL‐23 blockade achieved the highest PASI90 rates and longest drug survival versus both IL‐17 and TNF‐α inhibitors ( p < 0.05). In this real‐world cohort of Chinese psoriasis patients, BMI was observed to correlate with biologic effectiveness in a drug‐specific manner. Our findings suggest that whilst IL‐17 or IL‐23 inhibitors showed favourable outcomes for non‐overweight individuals, IL‐23 blockade may be associated with a more sustained response in those categorised as overweight or obese.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PsoriasisBody Mass IndexBiological ProductsHumansFemaleMaleTumor Necrosis Factor-alphaAdultInterleukin-17Middle AgedObesityInterleukin-23Severity of Illness IndexCohort StudiesTreatment OutcomeAntibodies, Monoclonal, Humanized

Stichwörter der Autor:innen

biologic agentsbody‐mass indexlong‐term efficacypsoriasisreal‐world study

Substanzen

Tumor Necrosis Factor-alphaInterleukin-17Interleukin-23Biological ProductsAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Dermatology, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China.

ORCID-Profile: Erle Dang, Chen Yu, Gang Wang

Zitieren

APA

Shen, X., Wang, F., Wang, R., Liu, H., Dang, E., Yu, C., & Wang, G. (2026). Biologic Efficacy by BMI in Moderate‐To‐Severe Psoriasis: A Real‐World Cohort Study. Experimental Dermatology, 35(4). https://doi.org/10.1111/exd.70252

Vancouver

Shen X, Wang F, Wang R, Liu H, Dang E, Yu C, et al. Biologic Efficacy by BMI in Moderate‐To‐Severe Psoriasis: A Real‐World Cohort Study. Experimental Dermatology. 2026;35(4). doi:10.1111/exd.70252

BibTeX
@article{Shen2026,
  author = {Shen, Xin and Wang, Fan and Wang, Rui and Liu, Huan and Dang, Erle and Yu, Chen and Wang, Gang},
  title = {Biologic Efficacy by BMI in Moderate‐To‐Severe Psoriasis: A Real‐World Cohort Study},
  journal = {Experimental Dermatology},
  year = {2026},
  volume = {35},
  number = {4},
  doi = {10.1111/exd.70252}
}
Kostenlos starten →